TB-500 Benefits: What the Research Actually Studied

By DoseGauge Editorial · Updated 2026-06-14 · 8 min read

What the research connected to TB-500 has actually studied is angiogenesis, wound healing, and tissue repair, demonstrated largely in cell and animal models of thymosin beta-4, the parent protein. That is different from the human injury-recovery benefits marketed in the peptide community, things like tendon and ligament healing and faster recovery, which no rigorous human outcome trial establishes. TB-500 itself is a short synthetic fragment of thymosin beta-4, it is not FDA-approved for any use, it is banned at all times in sport by the World Anti-Doping Agency, and human outcome data for it are essentially absent. This page reports what the research examined. It does not promise a result, and it is informational and educational only, not medical advice.

What the research has studied

The peer-reviewed reviews cited here are reviews of thymosin beta-4, the full 43-amino-acid protein, not of TB-500, the short Ac-LKKTETQ fragment sold in the peptide community. That distinction runs through everything below: a property reported for the parent protein is reasonable context for the fragment, because TB-500 is derived from that sequence, but it is not the same as a result demonstrated for the fragment itself. For more on the molecule, see what tb-500 is. With that framing fixed, here is what the reviews report the research examined. Each item is mostly a cell or animal finding, not a demonstrated human outcome for TB-500.

In angiogenesis, the formation of new blood vessels, the reviews describe thymosin beta-4 promoting vessel formation and supporting the viability, proliferation, and migration of endothelial and progenitor cells, with animal work in cardiac and limb ischemia models (Xing et al., 2021; Maar et al., 2021). In wound healing, the reviews describe thymosin beta-4 accelerating the rate of dermal repair, with cell and animal studies of keratinocyte migration and wound closure, and some Phase II dermal trials in pressure, venous, and stasis ulcers (Xing et al., 2021; Maar et al., 2021). For tissue and tendon repair more broadly, the evidence is largely preclinical: animal models of cardiac and other tissue injury report improved cell survival and repair (Maar et al., 2021). The reviews also describe cell migration and actin binding as the core mechanism, thymosin beta-4 acting as an actin-sequestering peptide that helps regulate cell movement, plus anti-inflammatory activity such as blocking NF-kappaB signaling, mostly in cell-culture and animal work (Xing et al., 2021; Maar et al., 2021).

Two points keep this accurate. First, the most developed human evidence for thymosin beta-4 sits in wound healing and ophthalmology (dermal ulcers, dry eye), reaching Phase II, not Phase III, and not in the tendon, ligament, or injury-recovery setting TB-500 is marketed for. Second, all of it studies the parent protein. None of it is an outcome trial of the TB-500 fragment.

Preclinical findings are not human outcomes

Preclinical findings are a reason to study a compound further. They are not proof that it works in people. There is a real gap between "thymosin beta-4 promoted vessel growth in a mouse heart" and "TB-500 will heal your tendon," and that gap is where most of the marketing lives.

A finding in cultured cells or in animals tells you what the molecule did under those conditions, in that biology. Whether the same effect appears in a human body, at a human dose, with controls and a measured outcome, is a separate question that has to be answered by trials designed to answer it. For TB-500, those trials do not exist. The reviews report human data for thymosin beta-4 only in narrow contexts (early-phase dermal wound and ophthalmic work), not for the injury-recovery uses TB-500 is sold for, and not for the fragment at all. A large share of compounds that look promising in animals fail to show the same effect when they finally reach controlled human trials, so an animal finding cannot be read as a human benefit. The accurate status is narrow and specific: TB-500 has been studied mostly through preclinical work on its parent protein for angiogenesis, wound healing, and tissue repair, and human outcome data for TB-500 itself are essentially absent.

What the marketed claims get ahead of

Being precise about the gaps is the whole point of this page. The claims commonly attached to TB-500 in the peptide community are tendon and ligament repair, injury recovery, and faster healing. For each one, the situation is the same: no rigorous human outcome trial demonstrates it for TB-500.

There is no rigorous human trial showing TB-500 heals tendons. There is no rigorous human trial showing it heals ligaments. There is no rigorous human trial showing it speeds recovery from injury. The preclinical results above are real findings, mostly in cells and animals and mostly in the parent protein, but they are not a substitute for any of these human outcomes, and they should not be presented as one. Even the human thymosin beta-4 work that does exist is early-phase and is in dermal wounds and the eye, not in the musculoskeletal injury-recovery setting the marketing describes.

In short, the marketed claims outrun the evidence. The research examined tissue-repair mechanisms in cells and animals; the marketing sells tendon and ligament healing and faster injury recovery in humans. Those are not the same thing, and TB-500 is not FDA-approved for any use, so there is no agency-reviewed efficacy record to fall back on either. Anyone presenting these human outcomes as established is presenting something the published evidence does not support.

A note on expectations and on sport

A preclinical mechanism is a reason for researchers to keep studying a compound. It is not a promise to an individual. The fact that thymosin beta-4 promoted angiogenesis in cells, or improved repair in an animal injury model, tells you what it did under those conditions. It does not tell you what will happen to a specific person, at a specific dose, over time, because that has not been studied in the trials it would take to know.

TB-500 is not FDA-approved for any indication. It is also prohibited at all times in sport by the World Anti-Doping Agency under the Prohibited List, category S2.3 (Growth Factors and Related Substances), so a competitive athlete who tests positive is subject to sanction regardless of intent. Whether any research peptide is appropriate for a particular person is a clinical question, and the right place to take it is a licensed clinician who knows your situation. For the safety picture, see side effects. DoseGauge does not assess benefit and does not recommend TB-500 for any purpose. The calculator on this site recommends no dose; it performs reconstitution and syringe-unit math on the numbers you enter and makes no claim about whether the compound produces any effect.

Frequently asked questions

What are the benefits of TB-500?

What the research has studied, mostly through preclinical work on its parent protein thymosin beta-4, is angiogenesis, wound healing, and tissue repair, largely in cell-culture and animal models (Xing et al., 2021; Maar et al., 2021). Those are preclinical findings, not proven human benefits for TB-500. No rigorous human outcome trial establishes the marketed tendon, ligament, or injury-recovery claims, and TB-500 is not FDA-approved for any use. This page reports the evidence and does not claim a benefit.

Does TB-500 heal injuries?

The molecule it is derived from, thymosin beta-4, has been studied for tissue repair and wound healing in cells and animals, and in early-phase dermal trials for skin ulcers (Xing et al., 2021; Maar et al., 2021). That is not the same as evidence that TB-500 heals injuries in people. No rigorous human outcome trial has shown that TB-500 produces injury recovery, and it is not FDA-approved for any indication. Treat the preclinical results as research context, not as a demonstrated human benefit.

Does TB-500 help tendons and ligaments?

Tendon and ligament repair are among the most common marketed claims for TB-500, but they are not established by rigorous human trials. The reviews describe tissue-repair mechanisms for thymosin beta-4 mostly in cells and animals, and the limited human thymosin beta-4 work is in dermal wounds and the eye, not in tendon or ligament healing (Xing et al., 2021; Maar et al., 2021). There is no controlled human trial showing TB-500 repairs tendons or ligaments, and it is not FDA-approved.

Is TB-500 proven to work in humans?

No. The supportive findings on angiogenesis, wound healing, and tissue repair come mostly from cell and animal studies of thymosin beta-4, the parent protein (Xing et al., 2021; Maar et al., 2021). The human data that exist are early-phase and in narrow contexts such as dermal ulcers and dry eye, not the marketed injury-recovery uses, and none of it is an outcome trial of the TB-500 fragment. TB-500 is not FDA-approved for any indication and is banned in sport by WADA. The accurate answer is that its effects in humans are unproven.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.